drugset / Trial / NCT00987935
A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is to evaluate the safety, appropriate dose, and efficacy of BIBF 1120 in liver cancer patients
Timeline
- Start
- 2009-10
- Primary completion
- 2014-07
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nintedanib | Small molecule | — | — |
| Comparator | Sorafenib | Small molecule | 400 mg | — |